Prostacyclins and analogues for the treatment of pulmonary hypertension in neonates
References
Additional references
Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long‐term continuous intravenous prostacyclin. Annals of Internal Medicine 1994;121(6):409‐15. [PUBMED: 8053614]
Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. New England Journal of Medicine 1996;334(5):296‐301. [PUBMED: 8532025]
Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 1999;99(9):1197‐208.
Bell MJ, Ternberg JL, Feigin RD, Keating JP, Marshall R, Barton L, et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Annals of Surgery 1978;187(1):1‐7. [PUBMED: 413500]
Bhat R, Salas AA, Foster C, Carlo WA, Ambalavanan N. Prospective analysis of pulmonary hypertension in extremely low birth weight infants. Pediatrics 2012;129(3):e682‐9.
Bos AP, Tibboel D, Koot VC, Hazebroek FW, Molenaar JC. Persistent pulmonary hypertension in high‐risk congenital diaphragmatic hernia patients: incidence and vasodilator therapy. Journal of Pediatric Surgery 1993;28(11):1463‐5. [PUBMED: 8301459]
Cabral JE, Belik J. Persistent pulmonary hypertension of the newborn: recent advances in pathophysiology and treatment. Jornal de Pediatria 2013;89(3):226‐42. [PUBMED: 23684454]
Committee for the Classification of Retinopathy of Prematurity. An International Classification of Retinopathy of Prematurity. Archives of Ophthalmology 1984;102(8):1130‐4. [PUBMED: 6547831]
Chotigeat U, Jaratwashirakul S. Inhaled iloprost for severe persistent pulmonary hypertension of the newborn. Journal of the Medical Association of Thailand 2007;90(1):167‐70. [PUBMED: 17621749]
Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. New England Journal of Medicine 1992;327(2):70‐5. [PUBMED: 1603138]
Cornfield DN, Chatfield BA, McQueston JA, McMurtry IF, Abman SH. Effects of birth‐related stimuli on L‐arginine‐dependent pulmonary vasodilation in ovine fetus. American Journal of Physiology 1992;262(5 Pt 2):H1474‐81. [PUBMED: 1590451]
De Luca D, Zecca E, Piastra M, Romagnoli C. Iloprost as 'rescue' therapy for pulmonary hypertension of the neonate. Paediatric Anaesthesia 2007;17(4):394‐5. [PUBMED: 17359413]
Doran AK, Ivy DD, Barst RJ, Hill N, Murali S, Benza RL. Guidelines for the prevention of central venous catheter‐related blood stream infections with prostanoid therapy for pulmonary arterial hypertension. International Journal of Clinical Practice. Supplement 2008;160:5‐9. [PUBMED: 18638170]
Dorris SL, Peebles RS. PGI2 as a regulator of inflammatory diseases. Mediators of Inflammation 2012;2012:926968.
Ehlen M, Wiebe B. Iloprost in persistent pulmonary hypertension of the newborn. Cardiology in the Young 2003;13(4):361‐3. [PUBMED: 14694957]
Extracorporeal Life Support Organization (ELSO). Guidelines for neonatal respiratory failure. ELSO Neonatal Respiratory Failure Supplement to the ELSO General Guidelines. Version 1.3. December 2013. www.elso.org/Portals/0/IGD/Archive/FileManager/8588d1a580cusersshyerdocumentselsoguidelinesforneonatalrespiratoryfailure13.pdf (accessed dd Month yyyy).
Ewert R, Schäper C, Halank M, Gläser S, Opitz CF. Inhalative iloprost ‐ pharmacology and clinical application. Expert Opinion on Pharmacotherapy 2009;10(13):2195‐207. [PUBMED: 19663611]
Gomberg‐Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. European Respiratory Journal 2008;31(4):891‐901. [PUBMED: 18378784]
McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed dd Month yyyy. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015.
Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Ivy DD, Claussen L, Doran A. Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil. American Journal of Cardiology 2007;99(5):696‐8.
Ivy DD, Doran AK, Smith KJ, Mallory GB, Beghetti M, Barst RJ, et al. Short‐ and long‐term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. Journal of the American College of Cardiology 2008;51(2):161‐9.
Ivy DD. Prostacyclin in the intensive care setting. Pediatric Critical Care Medicine 2010;11(2 Suppl):S41‐5. [PUBMED: 20216163]
Ivy DD, Abman SH, Barst RJ, Berger RM, Bonnet D, Fleming TR, et al. Pediatric pulmonary hypertension. Journal of the American College of Cardiology 2013;62(25 Suppl):D117‐26. [PUBMED: 24355636]
Jobe AH, Bancalari E. Bronchopulmonary dysplasia. American Journal of Respiratory and Critical Care Medicine 2001;163(7):1723‐9. [PUBMED: 11401896]
Jones RL, Qian Y, Wong HN, Chan H, Yim AP. Prostanoid action on the human pulmonary vascular system. Clinical and Experimental Pharmacology and Physiology 1997;24(12):969‐72. [PUBMED: 9406667]
Keller RL. Pulmonary hypertension and pulmonary vasodilators. Clinics in Perinatology 2016;43(1):187‐202.
Kelly LK, Porta NF, Goodman DM, Carroll CL, Steinhorn RH. Inhaled prostacyclin for term infants with persistent pulmonary hypertension refractory to inhaled nitric oxide. Journal of Pediatrics 2002;141(6):830‐32. [PUBMED: 12461501]
Lakshminrusimha S, Steinhorn RH. Pulmonary vascular biology during neonatal transition. Clinics in Perinatology 1999;26(3):601‐19. [PUBMED: 10494467]
Lakshminrusimha S. The pulmonary circulation in neonatal respiratory failure. Clinics in Perinatology 2012;39(3):655‐83. [PUBMED: 22954275]
Levy M, Celermajer DS, Bourges‐Petit E, Del Cerro MJ, Bajolle F, Bonnet. Add‐on therapy with subcutaneous treprostinil for refractory pediatric pulmonary hypertension. Journal of Pediatrics 2011;158(4):584‐8. [PUBMED: 21035821]
Majed BH, Khalil RA. Molecular mechanisms regulating the vascular prostacyclin pathways and their adaptation during pregnancy and in the newborn. Pharmacological Reviews 2012;64(3):540‐82. [PUBMED: 22679221]
McNulty MJ, Sailstad JM, Steffen RP. The pharmacokinetics and pharmacodynamics of the prostacyclin analog 15AU81 in the anesthetized beagle dog. Prostaglandins, Leukotrienes & Essential Fatty Acids 1993;48(2):159‐66. [PUBMED: 8446654]
Mourani PM, Sontag MK, Younoszai A, Ivy DD, Abman SH. Clinical utility of echocardiography for the diagnosis and management of pulmonary vascular disease in young children with chronic lung disease. Pediatrics 2008;121(2):317‐25.
Mourani PM, Sontag MK, Younoszai A, Miller JI, Kinsella JP, Baker CD, et al. Early pulmonary vascular disease in preterm infants at risk for bronchopulmonary dysplasia. American Journal of Respiratory and Critical Care Medicine 2015;191(1):87‐95.
Nakayama T, Shimada H, Takatsuki S, Hoshida H, Ishikita T, Matsuura H, et al. Efficacy and limitations of continuous intravenous epoprostenol therapy for idiopathic pulmonary arterial hypertension in Japenese children. Circulation Journal 2007;71(11):1785‐90. [PUBMED: 17965503]
Nakwan N, Nakwan N, Wannaro J. Persistent pulmonary hypertension of the newborn successfully treated with beraprost sodium: a retrospective chart review. Neonatology 2011;99(1):32‐7.
Nuntnarumit P, Yang W, Bada‐Ellzey HS. Blood pressure measurements in the newborn. Clinics in Perinatology 1999;26(4):981‐96. [PUBMED: 10572732]
Olschewski H, Rose F, Schermuly R, Ghofrani HA, Enke B, Olschewski A, et al. Prostacyclin and its analogues in the treatment of pulmonary hypertension. Pharmacology & Therapeutics 2004;102(2):139‐53.
Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. Journal of Pediatrics 1978;92(4):529‐34. [PUBMED: 305471]
Payne AH, Hintz SR, Hibbs AM, Walsh MC, Vohr BR, Bann CM, et al. Neurodevelopmental outcomes of extremely low‐gestational‐age neonates with low‐grade periventricular‐intraventricular hemorrhage. JAMA Pediatrics 2013;167(5):451‐9. [PUBMED: 23460139]
Porta NFM, Steinhorn RH. Pulmonary vasodilator therapy in the NICU: inhaled nitric oxide, sildenafil, and other pulmonary vasodilating agents. Clinics in Perinatology 2012;39(1):149‐64. [PUBMED: 22341543]
Putensen C, Hormann C, Kleinsasser A, Putensen‐Himmer G. Cardiopulmonary effects of aerosolized prostaglandin E1 and nitric oxide inhalation in patients with acute respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine 1998;157(6 Pt 1):1743‐7.
Read NG, Radomski MW, Goodwin DA, Moncada S. An ultrastructural study of stored human platelets after washing using prostacyclin. British Journal of Haematology 1985;60(2):305‐14. [PUBMED: 3890933]
Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Rosenzweig EB, Kerstein D, Barst RJ. Long‐term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999;99(14):1858‐65. [PUBMED: 10199883]
Rubin LJ, Mendoza J, Hood M, McGoon M, Barst R, Williams WB, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Annals of Internal Medicine 1990;112(7):485‐91. [PUBMED: 2107780]
Schünemann H, Brożek J, Guyatt G, Oxman A, editors. GRADE Working Group. GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. Available from https://gdt.gradepro.org/app/handbook/handbook.html (accessed dd Month yyyy).
Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Hervé P, et al. Long‐term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. Journal of the American College of Cardiology 2002;40(4):780‐8. [PUBMED: 12204511]
Steinhorn RH. Pharmacotherapy for pulmonary hypertension. Pediatric Clinics of North America 2012;59(5):1129‐46. [PUBMED: 23036248]
Storme L, Aubry E, Rakza T, Houeijeh A, Debarge V, Tourneux P, et al. Pathophysiology of persistent pulmonary hypertension of the newborn: impact of the perinatal environment. Archives of Cardiovascular Diseases 2013;106(3):169‐77. [PUBMED: 23582679]
Teitel DF, Iwamoto HS, Rudolph AM. Changes in the pulmonary circulation during birth‐related events. Pediatric Research 1990;27(4 Pt 1):372‐8. [PUBMED: 2342829]
Vane JR, Botting RM. Pharmacodynamic profile of prostacyclin. American Journal of Cardiology 1995;75(3):3A‐10A. [PUBMED: 7840052]
Vane J, Corin RE. Prostacyclin: a vascular mediator. European Journal of Vascular and Endovascular Surgery 2003;26(6):571‐8. [PUBMED: 14603414]
Volpe JJ. Neurology of the Newborn. 5th Edition. Philadelphia: WB Saunders, 2008:347‐99.
Walsh‐Sukys MC, Tyson JE, Wright LL, Bauer CR, Korones SB, Stevenson DK, et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics 2000;105(1 Pt 1):14‐20. [PUBMED: 10617698]
Wharton J, Davie N, Upton PD, Yacoub MH, Polak JM, Morrell NW. Prostacyclin analogues differentially inhibit growth of distal and proximal human pulmonary artery smooth muscle cells. Circulation 2000;102(25):3130‐6. [PUBMED: 11120706]
Yung D, Widlitz AC, Rosenzweig EB, Kerstein D, Maislin G, Barst RJ. Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation 2004;110(6):660‐5. [PUBMED: 15289375]
